

January 14, 2026

Company Name: MANI, INC.
Representative: Masaya Watanabe
Director, President & Representative
Executive Officer
Security Code: 7730, Prime Market of TSE
Inquiries: Takayuki Yamamoto
Managing Executive Officer, CFO
TEL: +81-28-667-1811

Notice Regarding Establishment of Chinese Manufacturing Subsidiary

MANI, INC. (hereinafter "MANI") hereby announce that at the Board of Directors meeting held today, MANI resolved to establish a wholly owned production subsidiary in Foshan, Guangdong Province, China. This decision is aimed at responding to the preferential policies for domestic products in the Chinese market and strengthening our competitiveness.

1. Background and Purpose

In recent years, China has been strengthening its preferential policies for domestically produced medical devices, with the adoption rate of domestic products increasing in government procurement and major hospitals. For example, in the field of ophthalmic knives for cataract surgery, one of our main products, there is a growing requirement for the adoption of domestic products in public and major private chain hospitals, and this trend is expected to continue. Furthermore, with the introduction of the national volume-based procurement system by the Chinese government, domestic products are favored in terms of pricing, while imported products face a more challenging competitive environment in terms of both sales volume and price.

In response to these changes, we believe it is necessary to establish a local production base in China to maintain our existing market share and achieve sustainable growth, enabling us to respond quickly to local policies and customer needs. The new factory in China will incorporate automation technologies developed at our Smart Factory, while managing investment risks by renting the factory building.

In the medium to long term, we aim to establish a global three-site production system: the Hanaoka Smart Factory as the mother factory, the Vietnam factory as the global mass production site, and the new China factory as the local production site for the Chinese market, thereby enhancing our global competitiveness.

2. Overview of the New Subsidiary


Item	Details
Name (tentative)	MANI China (Foshan) Co., Ltd.
Representative	Jiao Weiran
Location	Foshan, Guangdong Province, People's Republic of China
Business Description	Manufacturing of ophthalmic knives and related products for the Chinese market
Scheduled Establishment	April 2026
Scheduled Start of Mass Production	March 2028

Fiscal Year End	August 31
Capital	RMB 32 million
Shareholders ratio	100% owned by MANI, INC.

3. Impact on Consolidated Results

The establishment of the new factory in China will involve a total capital investment of approximately ¥1.2 billion. The impact has already been incorporated into our capital investment plan and consolidated earnings forecast for the fiscal year ending August 31, 2026. Should any matters requiring disclosure arise, we will promptly make an announcement.

[Reference] Global Three-Site Production System



Disclaimer:

This English translation has been prepared for general reference purposes only.

In the event of any discrepancy between the English translated document and the original Japanese document, the original document shall prevail.